Hybrid Ablation of Atrial Fibrillation in Heart Failure

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT05411614

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
St. George's Hospital, London (from the registry)
Registry
  • NCT NCT05411614
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05411614. Randomized; single masking; primary purpose treatment. Start 2022-06-25 (actual); primary completion 2026-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Hybrid Ablation of Atrial Fibrillation in Heart Failure
Acronym
HALT AF
Condition
Persistent Atrial Fibrillation
Condition
Atrial Fibrillation, Persistent
Condition
Atrial Arrhythmia
Condition
Atrial Fibrillation
Condition
Heart Failure
Condition
Left Ventricular (LV) Systolic Dysfunction
Intervention (Device)
AtriCure EPi-Sense-AF Guided Coagulation System +/- Atriclip
Intervention (Device)
Endocardial Catheter Ablation
Lead sponsor
St. George's Hospital, London (class: other)

Record details

Record id
cardio:ct-nct05411614
Content hash
e9ff1274083408093142ed18a44db8a965cc6a63832ff719562b26303d43d6c6